Clinical trial · Interventional
Chemotherapy and Proton Radiation for the Treatment of Locally Advanced Lung Cancer
Phase I/II Study of Combined Chemotherapy and High Dose, Accelerated Proton Radiation for the Treatment of Locally Advanced Non-Small Cell Lung Carcinoma
NCT00614484CI-TRIAL-00014668terminatedPhase 1 / Phase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Low participant enrollment rates. Significant comparative data not obtained.
Summary
Brief summary (as posted)
The purpose of this study is to determine the effectiveness of proton beam radiotherapy combined with chemotherapy for treatment of locally advanced non-small cell lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Locally Advanced Non-Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Carboplatin | Drug | Carboplatin | ALIAS |
| Proton Radiation Therapy | Radiation | — | UNRESOLVED |
| Taxol | Drug | Taxol | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Proton therapy with chemotherapy
- description
- Induction Chemotherapy - Two cycles Taxol 200mg/m2 and Carboplatin AUC6 on day 1 and day 22. Weekly chemotherapy concurrent with radiotherapy Taxol 50mg/m2 and Carboplatin AUC 2 weekly for 5 weeks. Proton therapy - 76 Gy in 5 weeks to lung tumor.
- interventionNames
- Radiation: Proton Radiation Therapy
- Drug: Taxol
- Drug: Carboplatin
Primary outcomes (1)
- measure
- Overall Survival.
- timeFrame
- Monthly for duration of participant lifespan. Average lifespan 1-2 years
- description
- Median survival time following treatment.
Secondary outcomes (1)
- measure
- Treatment Related Toxicities.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Clinical stage 2, 3A or 3B (unresectable) * Histologic evidence of non-small cell carcinoma * Age \> 18 years * Karnofsky performance status 70 or greater * No prior radiation to the chest * No previous chemotherapy Exclusion Criteria: * Clinical stage 1 or 4 * Previous malignancies except for non-melanoma skin cancer unless disease free for \> 3 years
References
Publications (0)
Data not yet available
No reference posted for this study.